scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025
Rhea-AI Summary
scPharmaceuticals (NASDAQ: SCPH), a pharmaceutical company focused on cardiorenal healthcare innovations, has scheduled its Q2 2025 financial results announcement for August 7, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the quarterly results and provide business updates.
Interested participants can join via phone using the toll-free number (800) 715-9871 or toll number (646) 307-1963 with passcode 4965353. The webcast will be available through the company's Investor Relations section on their website.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, SCPH gained 1.77%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Management to host conference call and webcast, after-market on August 7, 2025, at 4:30 p.m. ET
BURLINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 7, 2025, to discuss the financial results for the second quarter 2025 and provide a business update.
A link to the live webcast can be found here.
Participants should dial (800) 715-9871 (toll-free) or (646) 307-1963 (toll) and use the passcode 4965353
The live webcast and replay of the conference call can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.
About scPharmaceuticals
At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs.
Our goal is to become the foremost advocate for patient-centric cardiorenal care, driving global health improvements through specialized, multidisciplinary approaches. scPharmaceuticals is expanding its reach, offering integrated therapies and products that address diverse healthcare needs and potentially improve the lives of our patients. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Katherine Miranda
scPharmaceuticals Inc., (781) 301-6869
kmiranda@scpharma.com
Investors:
Matthew Beck
astr partners, (917) 415-1750
matthew.beck@astrpartners.com
FAQ
When will scPharmaceuticals (SCPH) release Q2 2025 earnings?
How can I join the scPharmaceuticals Q2 2025 earnings call?
What time is the SCPH Q2 2025 earnings conference call?
Where can I access the replay of SCPH's Q2 2025 earnings call?
